SCHEDULE: Vanguard Group Adjusts ArriVent Biopharma Stake Below 5%

The Vanguard Group reported a beneficial ownership of 4.52% in ArriVent Biopharma Inc. as of December 31, 2025, following an internal realignment.

Summary

• The Vanguard Group beneficially owns 1,869,266 shares of ArriVent Biopharma Inc. Common Stock.
• This ownership represents 4.52% of the class of securities as of December 31, 2025.
• Vanguard holds shared voting power over 242,661 shares and shared dispositive power over 1,869,266 shares.
• An internal realignment occurred at The Vanguard Group, Inc. on January 12, 2026.
• Post-realignment, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting.
• Certain Vanguard subsidiaries or business divisions will now report beneficial ownership separately (disaggregated basis) in reliance on SEC Release No. 34-39538.
• These subsidiaries and business divisions will continue to pursue the same investment strategies as previously held by The Vanguard Group, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. While the aggregate ownership dropped below 5%, the explanation of an internal realignment and continued investment strategies by subsidiaries mitigates concerns of a negative outlook on ArriVent Biopharma Inc.

Positives

• The continued beneficial ownership by The Vanguard Group's subsidiaries, pursuing the same investment strategies, indicates ongoing institutional confidence in ArriVent Biopharma Inc.

Negatives

• The reported beneficial ownership of 4.52% signifies that The Vanguard Group's aggregate stake has fallen below the 5% threshold, which could be interpreted as a reduction in a significant institutional position, although explained by internal realignment.

Risks

• The internal realignment at The Vanguard Group could lead to a temporary period of uncertainty regarding how its various investment vehicles' holdings in ArriVent Biopharma Inc. will be aggregated or perceived by the market, despite assurances of consistent investment strategies.

Future Outlook

The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately on a disaggregated basis following the internal realignment, continuing to pursue the same investment strategies.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings provide transparency into significant passive institutional ownership. While a reduction below the 5% threshold might typically signal a shift in investor sentiment, Vanguard's explanation of an internal realignment and disaggregated reporting suggests this is an administrative change rather than a fundamental re-evaluation of ArriVent Biopharma Inc.'s prospects. This type of administrative adjustment by large asset managers is not uncommon.

Stakeholder Impact

• Shareholders: The change in reporting structure by a major institutional investor like Vanguard could lead to questions about the stability of institutional holdings, though the underlying investment strategies remain consistent.
• Investment Professionals: Analysts will need to consider the disaggregated reporting from Vanguard's subsidiaries for a complete picture of institutional ownership.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately on a disaggregated basis in future filings.

Key Dates

Recommendation

The filing primarily details an administrative change in how The Vanguard Group reports its beneficial ownership, rather than a fundamental shift in its investment thesis for ArriVent Biopharma Inc. The reduction below 5% is explained by an internal realignment, with subsidiaries continuing the same investment strategies. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment stance based on company fundamentals.

Keywords

ArriVent Biopharma, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, SEC Filing